BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

Benzinga · 2d ago
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.